Read short summaries of the latest research published by Oncotarget.
Oncotarget’s Volume 12, Issue #9
New Publications
Cover (Research Paper): Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore
Origin: Connecticut, United States
Institutions: Yale University School of Medicine
Quote: “Here, we show that mibefradil inhibits DNA repair independent of its CCB activity, and report a series of mibefradil analogues which lack CCB activity and demonstrate reduced hERG and CYP activity while retaining potency as DNA repair inhibitors. We present in vivo pharmacokinetic studies of the top analogues with evidence of brain penetration.”
Editorial Paper (PDF download): Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
Origin: Massachusetts, Washington, United States
Institution: Dana-Farber Cancer Institute, Medstar Washington Hospital Center
Quote: “The treatment of BCBM [Breast cancer brain metastases] is based mostly on local therapies and there is an unmet need for systemic therapies for these patients, particularly for those with human epidermal growth factor receptor 2 positive (HER2+) tumors and for patients with LMD.”
Editorial Paper (PDF download): Epigenetic effects of pharmacologic ascorbate
Origin: Iowa, United States
Institution: University of Iowa Hospitals and Clinics
Quote: “Recently, pharmacologic ascorbate (ascorbic acid, ascorbate, P-AscH-) given at high intravenous doses has been investigated as an adjuvant to chemotherapy and radiation therapy in the treatment of pancreatic cancer. P-AscH- has been shown to act as an oxidizing agent at high doses, generating hydrogen peroxide (H2O2) to cancer cells resulting in selective cytotoxicity while protecting normal tissue [2–8].”
Research Paper: Activation of plasmacytoid dendritic cells promotes AML-cell fratricide
Origin: Ohio, United States
Institution: The Ohio State University
Quote: “Here, we examined the effects of the TLR7/8 agonist R848 on the phenotype and cytokine production of AML-patient pDCs. In agreement with previous studies [19] we found that R848 led to higher expression of CD40. Notably, it also increased IFNβ production by AML-patient pDCs, and this induced an upregulation of CD38 in AML cells.”
Research Paper: Piperlongumine promotes death of retinoblastoma cancer cells
Origin: Sion, Lausanne, Switzerland
Institution: Institute for Research in Ophthalmology, University of Lausanne, Ecole Polytechnique Fédérale de Lausanne
Quote: “In this report, we analyzed the pro-death effect of piperlongumine (PL), a natural compound isolated from Piper longum L., on two human retinoblastoma cell lines, WERI-Rb and Y79. The effects of PL on cell proliferation, cell death and cell cycle were investigated.”
Research Paper: A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer
Origin: Yokohama, Japan
Institutions: Yokohama Minami Kyousai Hospital, Yokohama City University Medical Center, Yokohama City University Graduate School of Medicine
Quote: “High-risk non-muscle invasive bladder cancer (NMIBC) is thought to be associated with a higher risk of recurrence and progression. A recent study revealed that a high De Ritis ratio was a risk factor in some solid malignancies. This study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC.”
Research Paper: Down regulation of lactate dehydrogenase initiates apoptosis in HeLa and MCF-7 cancer cells through increased voltage-dependent anion channel protein and inhibition of BCL2
Origin: AlAin, United Arab Emirates
Institution: United Arab Emirates University
Quote: “Malignant cells commonly use aerobic glycolysis for ATP production; this is known as the Warburg effect, where pyruvate is converted to lactate, by enzyme lactate dehydrogenase A (LDH-A). In this study, we have investigated the effect of inhibition of LDH-A on cells viability and identifying the mechanism of cell death in HeLa and MCF-7 cancer cells.”
Review Paper: Multigene tests for breast cancer: the physician’s perspective
Origin: Rome, Prato, Napoli, Genova, Rome, Milan, Bologna, Bergamo, Italy
Institution: La Sapienza University, Hospital of Prato, Università degli Studi di Napoli Federico II, IRCCS AOU San Martino – IST Istituto Nazionale per la Ricerca del Cancro, Catholic University, La Sapienza University, Fondazione IRCCS Istituto Nazionale Tumori, IRCCS Azienda Ospedaliera Universitaria di Bologna, Papa Giovanni XXIII Hospital, Humanitas Cancer Center,School University Campus Bio-Medico, ASST Bergamo Ovest
Quote: “Besides clinical and pathological factors, today four multigene tests able to guide the choice of the adjuvant therapy early breast cancer are available in Italy: Oncotype DX®, EndoPredict®, MammaPrint® e Prosigna®. This review evaluates the main characteristics of these diagnostic tests, the studies on clinical utility, their economic impact and their inclusion in international and national guidelines.”
Click here to read Oncotarget’s Volume 12, Issue #9
—
Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read—without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.
For media inquiries, please contact media@impactjournals.com.
